Picture of Armata Pharmaceuticals logo

ARMP Armata Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m+205.5%
3m+4.73%
6m-16.05%
1yr-32.96%
Volume Change (%)
10d/3m+50.41%
Price vs... (%)
52w High-41.11%
50d MA+67.94%
200d MA-3.07%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-38.04%
Return on Equity-94.18%
Operating Margin-599.82%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Armata Pharmaceuticals EPS forecast chart

Profile Summary

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis (NCFB), prosthetic joint infections (PJI) and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
March 9th, 1989
Public Since
May 20th, 1994
No. of Shareholders
99
No. of Employees
69
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
36,144,706

ARMP Share Price Performance

Upcoming Events for ARMP

Q4 2022 Armata Pharmaceuticals Inc Earnings Release

Q1 2023 Armata Pharmaceuticals Inc Earnings Release

Similar to ARMP

FAQ

Or unlock with your email

Or unlock with your email